ACZ885 for the Treatment of Abdominal Aortic Aneurysm (AAA)
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study of Subcutaneous ACZ885 for the Treatment of Abdominal Aortic Aneurysm
Sponsor: Novartis Pharmaceuticals
Terminated
The results of a third interim analysis (ad hoc) indicated a lack of efficacy and futility in continuing the trial.
This PHASE2 trial investigates Abdominal Aortic Aneurysm (AAA) and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 13 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Feb 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
May 2019 — Nov 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — May 2019 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .